Neurotrope Inc (NASDAQ:NTRP) has earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Brokers have set a 1-year consensus target price of $16.00 for the company, according to Zacks. Zacks has also given Neurotrope an industry rank of 184 out of 255 based on the ratings given to its competitors.

A number of research analysts have recently issued reports on the stock. Maxim Group set a $16.00 price target on shares of Neurotrope and gave the stock a “buy” rating in a research report on Monday, July 2nd. Zacks Investment Research upgraded shares of Neurotrope from a “sell” rating to a “hold” rating in a research report on Thursday, June 28th. Finally, ValuEngine downgraded shares of Neurotrope from a “buy” rating to a “hold” rating in a research report on Monday, July 2nd.

Several hedge funds and other institutional investors have recently modified their holdings of NTRP. Neville Rodie & Shaw Inc. acquired a new position in shares of Neurotrope in the 2nd quarter worth approximately $1,059,000. Ingalls & Snyder LLC acquired a new position in shares of Neurotrope in the 2nd quarter worth approximately $326,000. Cannell Peter B & Co. Inc. lifted its position in shares of Neurotrope by 14.2% in the 1st quarter. Cannell Peter B & Co. Inc. now owns 270,793 shares of the company’s stock worth $2,199,000 after purchasing an additional 33,600 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Neurotrope during the 2nd quarter valued at $281,000. Finally, Tanaka Capital Management Inc. lifted its position in shares of Neurotrope by 12.1% during the 2nd quarter. Tanaka Capital Management Inc. now owns 198,195 shares of the company’s stock valued at $1,919,000 after acquiring an additional 21,455 shares during the period. Hedge funds and other institutional investors own 16.83% of the company’s stock.

NTRP traded down $0.51 during trading on Tuesday, reaching $8.05. 23,100 shares of the company’s stock were exchanged, compared to its average volume of 26,085. Neurotrope has a one year low of $3.97 and a one year high of $11.93.

Neurotrope (NASDAQ:NTRP) last issued its quarterly earnings results on Friday, August 10th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.12.

About Neurotrope

Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease (AD). Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C.

Further Reading: Penny Stocks

Get a free copy of the Zacks research report on Neurotrope (NTRP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.